Neurogene Inc. Income Statement
NGNE|4 years of annual SEC 10-K data (FY2018-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 4 fiscal years. All figures from audited SEC 10-K filings.
Neurogene Inc. reported $925,000 in revenue and $75M in net loss for FY2025. Revenue has declined at a 37.6% compound annual rate over the past 7 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -6.24 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2019 | FY2018 |
|---|---|---|---|---|
| Revenue | $925.0K | $0 | $25.0M | $25.0M |
| SG&A Expense | $22.6M | $11.2M | $14.9M | $9.3M |
| R&D Expense | $60.9M | $44.4M | - | $28.4M |
| Operating Income | -$82.6M | -$55.6M | -$51.1M | -$37.6M |
| Interest Expense | - | - | $4.0K | $1.0K |
| Income Tax | $0 | - | - | - |
| Net Income | -$75.1M | -$36.3M | -$50.2M | -$37.0M |
| EPS (Basic) | -$4.28 | -$4.28 | - | - |
| EPS (Diluted) | -$4.28 | -$4.28 | -$2.14 | -$1.96 |
| Shares Outstanding | 14.9M | 12.8M | 23.5M | 23.5M |
| Operating Margin | -8930.3% | - | -204.5% | -150.6% |
| Profit Margin | -8123.7% | - | -200.7% | -148.0% |